Haihe Pharma is a Shanghai biotech focused on discovery, development and commercialization of innovative oncology therapies. The company says it has 11 core products, eight in clinical development and five accepted for IND by U.S. regulators; it currently lists eight clinical-stage compounds and three preclinical compounds. Haihe has built a precision‑medicine platform guided by biomarkers and a full preclinical and clinical research system covering CMC, biomarker discovery/validation, medical strategy and clinical research. Management is led by a team that includes a Chinese Academy of Engineering academician. The company is accelerating international development and commercial readiness for its pipeline. Funds from the recent round will be used to speed global R&D and product launches across multiple anti‑tumor programs.

Total raised

$171M

Funding rounds

1

Latest round

Series B

Latest activity

Jul 2020